MCM3 and breast cancer: Taken together, the results suggest that MCM3, in addition to being a predictive marker of tamoxifen benefit in ER+ breast cancer, is a more consistent prognostic marker in ER+ breast cancer than Ki67, and may add information to clinical decision-making beyond that of Ki67.